{"product_id":"pe-22-28","title":"PE-22-28 10mg - TREK-1 Modulation and Neuroplasticity Research Peptide","description":"\u003cp\u003e\u003cstrong\u003ePE-22-28 (CAS 1801959-12-5)\u003c\/strong\u003e is a synthetic seven-amino-acid research peptide developed from investigations into endogenous neuronal signaling pathways. The peptide is derived from studies of the TREK-1 potassium channel, a key regulator of neuronal excitability and serotonergic activity within the central nervous system.\u003c\/p\u003e\n\u003cp\u003eResearchers are investigating PE-22-28 for its ability to modulate neuronal firing patterns, influence serotonin signaling, and support neuroplasticity-related pathways. Unlike many traditional approaches that indirectly affect serotonergic systems, PE-22-28 acts upstream through TREK-1 modulation, producing rapid changes in neuronal excitability in preclinical models.\u003c\/p\u003e\n\u003cp\u003eAnimal research has demonstrated increased serotonergic activity alongside enhanced hippocampal neurogenesis, making PE-22-28 a valuable research tool for exploring the relationship between neuronal signaling, cognitive function, stress adaptation, and brain resilience. The peptide's compact seven-amino-acid structure also provides practical advantages for synthesis, purification, and analytical characterization.\u003c\/p\u003e\n\u003cp\u003eOverall, PE-22-28 represents an emerging molecular tool for studying the interaction between ion-channel regulation, neurotransmitter signaling, neuroplasticity, and activity-dependent neuronal adaptation.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eMolecular Mechanisms of Action at the Molecular Level\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003ePE-22-28 functions primarily through inhibition of the TREK-1 potassium channel, a member of the two-pore-domain potassium channel family expressed in serotonergic neurons of the dorsal raphe nucleus as well as various limbic and cortical brain regions.\u003c\/p\u003e\n\u003cp\u003eUnder physiological conditions, TREK-1 generates a background potassium leak current that helps stabilize neuronal membrane potential and limits spontaneous neuronal firing. By reducing potassium efflux through TREK-1, PE-22-28 induces a modest depolarization of the neuronal membrane, increasing the likelihood that neurons reach action-potential threshold.\u003c\/p\u003e\n\u003cp\u003eThis enhanced excitability elevates firing rates within serotonergic neurons and promotes calcium influx through voltage-gated calcium channels. Increased intracellular calcium subsequently supports vesicular release of serotonin into projection areas including the prefrontal cortex, hippocampus, and amygdala.\u003c\/p\u003e\n\u003cp\u003eElevated serotonergic signaling engages multiple downstream receptor systems, particularly 5-HT1A and 5-HT7 receptor populations. Activation of these receptors influences intracellular second-messenger networks involving cyclic adenosine monophosphate (cAMP), protein kinase signaling, and CREB phosphorylation.\u003c\/p\u003e\n\u003cp\u003eCREB activation promotes transcription of brain-derived neurotrophic factor (BDNF), one of the most extensively studied regulators of neuronal plasticity. Increased BDNF expression subsequently activates TrkB receptors and downstream PI3K-Akt and Ras-MAPK signaling cascades.\u003c\/p\u003e\n\u003cp\u003eAkt signaling supports cellular survival pathways while also influencing mTOR-dependent protein synthesis. These processes contribute to increased production of proteins involved in synaptic structure and communication, including PSD-95 and synapsin.\u003c\/p\u003e\n\u003cp\u003eThe combined effect is reinforcement of existing synaptic networks, maturation of dendritic spines, enhancement of long-term potentiation, and support for activity-dependent neuronal remodeling.\u003c\/p\u003e\n\u003cp\u003eIn parallel, PE-22-28 influences adult hippocampal neurogenesis. Neural progenitor cells located within the dentate gyrus respond to increased network activity and BDNF signaling through enhanced proliferation, survival, and differentiation into mature granule neurons.\u003c\/p\u003e\n\u003cp\u003ePreclinical studies suggest that these neuroplastic adaptations occur on a relatively compressed timeline compared with traditional monoaminergic interventions, making PE-22-28 particularly interesting for investigations involving rapid neuroplasticity mechanisms.\u003c\/p\u003e\n\u003cp\u003eThe peptide's short amino-acid sequence also offers significant advantages from a peptide chemistry perspective. Standard solid-phase synthesis techniques achieve high coupling efficiency, excellent purity, and straightforward scale-up while allowing future structural modifications designed to optimize stability or pharmacokinetic properties.\u003c\/p\u003e\n\u003cp\u003eAdditional downstream effects observed in experimental systems include activation of cell-survival pathways associated with PI3K-Akt signaling and improved resilience against oxidative and excitotoxic stress within neuronal cultures. Collectively, these molecular actions connect acute modulation of neuronal excitability with longer-term structural and transcriptional adaptations associated with neuroplasticity.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003ePotential Research Applications\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eThe molecular profile of PE-22-28 positions it as a valuable research tool for studying conditions and biological processes associated with altered serotonergic signaling, impaired neuroplasticity, and reduced hippocampal adaptability.\u003c\/p\u003e\n\u003cp\u003eOne of the primary areas of interest involves investigation of brain networks associated with emotional regulation and stress adaptation. Because TREK-1 plays a central role in regulating neuronal excitability within serotonergic circuits, modulation of this channel provides researchers with a unique opportunity to examine how membrane potential influences neurotransmitter release and downstream neuroplastic responses.\u003c\/p\u003e\n\u003cp\u003eThe peptide is also being explored in research models focused on hippocampal function. The hippocampus serves as a critical structure involved in learning, memory formation, cognitive flexibility, and adaptation to environmental stressors. Enhanced neurogenesis and synaptic remodeling observed in preclinical models suggest potential relevance for studies investigating age-related cognitive changes, stress-induced neuronal remodeling, and activity-dependent learning mechanisms.\u003c\/p\u003e\n\u003cp\u003eAdditional areas of interest include investigation of neuronal resilience under conditions of oxidative stress, inflammation, and excitotoxic challenge. Increased BDNF expression and activation of PI3K-Akt signaling pathways may contribute to cellular adaptations that support neuronal survival and structural integrity in experimental systems.\u003c\/p\u003e\n\u003cp\u003eResearchers are also utilizing PE-22-28 to better understand the relationship between ion-channel regulation and activity-dependent gene expression. The peptide provides a tractable model for examining how changes in neuronal firing patterns influence downstream transcriptional programs associated with synaptic plasticity and network remodeling.\u003c\/p\u003e\n\u003cp\u003eIts compact structure additionally makes PE-22-28 an attractive candidate for medicinal chemistry research, where analog development may be used to investigate improved stability, receptor selectivity, blood-brain barrier penetration, and pharmacokinetic properties while preserving TREK-1 inhibitory activity.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eSummary of Animal and Human Trials\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003ePreclinical research involving PE-22-28 has focused primarily on validated rodent models examining neuronal plasticity, hippocampal neurogenesis, and serotonergic signaling.\u003c\/p\u003e\n\u003cp\u003eIn multiple behavioral paradigms, including the forced-swim test and novelty-suppressed feeding model, animals receiving PE-22-28 demonstrated significant changes in behavioral endpoints associated with serotonergic modulation. Notably, these effects appeared within a relatively short timeframe compared with traditional monoaminergic interventions studied under similar experimental conditions.\u003c\/p\u003e\n\u003cp\u003eChronic stress models have produced particularly interesting findings. In rodents exposed to prolonged corticosterone administration, PE-22-28 reversed several stress-associated behavioral alterations while restoring measures of hippocampal adaptability. Histological analysis revealed substantial increases in BrdU-positive cells within the dentate gyrus after only a few days of peptide exposure, indicating accelerated neurogenic activity.\u003c\/p\u003e\n\u003cp\u003eMolecular investigations further demonstrated elevated hippocampal expression of brain-derived neurotrophic factor (BDNF) together with increased expression of synaptic proteins including PSD-95 and synapsin. These findings support the hypothesis that PE-22-28 influences both structural and functional components of neuronal plasticity.\u003c\/p\u003e\n\u003cp\u003eStudies performed in primary neuronal cultures showed enhanced dendritic spine maturation and increased markers of synaptogenesis. Electrophysiological recordings confirmed that TREK-1 inhibition directly increased firing rates within serotonergic neurons of the dorsal raphe nucleus, establishing a mechanistic link between ion-channel modulation and downstream neurotransmitter signaling.\u003c\/p\u003e\n\u003cp\u003eComparative investigations with the parent peptide spadin demonstrated that the shortened seven-amino-acid sequence retains strong TREK-1 inhibitory activity while offering practical advantages related to synthesis, purification, and manufacturing consistency.\u003c\/p\u003e\n\u003cp\u003eAcross reported preclinical studies, investigators observed no significant evidence of sedation, motor impairment, or overt toxicity under the dosing conditions examined.\u003c\/p\u003e\n\u003cp\u003eAt present, no completed human clinical trials have been identified for PE-22-28. Available evidence originates from in-vitro systems and animal research models. Human pharmacokinetic, safety, tolerability, and efficacy data remain unavailable.\u003c\/p\u003e\n\u003cp\u003eAs a result, PE-22-28 continues to be regarded as an investigational research peptide requiring additional preclinical characterization and future translational evaluation.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eWhy PE-22-28 Is Interesting: Mechanistic Arguments\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003ePE-22-28 is particularly interesting because it links rapid changes in neuronal excitability with longer-term structural adaptations associated with neuroplasticity.\u003c\/p\u003e\n\u003cp\u003eThe peptide acts at the level of ion-channel regulation by inhibiting TREK-1, producing immediate effects on membrane potential and neuronal firing activity. This initial modulation increases serotonergic signaling throughout interconnected brain networks.\u003c\/p\u003e\n\u003cp\u003eEnhanced serotonergic activity subsequently activates downstream pathways that promote CREB phosphorylation, BDNF expression, and TrkB signaling. These molecular events support synaptic remodeling, dendritic spine maturation, and activity-dependent transcriptional programs associated with neuronal adaptation.\u003c\/p\u003e\n\u003cp\u003eSimultaneously, increased BDNF-TrkB signaling promotes proliferation, survival, and differentiation of neural progenitor cells within the hippocampus. This creates a biological bridge between acute neurotransmitter signaling and longer-term network restructuring.\u003c\/p\u003e\n\u003cp\u003eUnlike approaches that focus exclusively on neurotransmitter availability or receptor activation, PE-22-28 influences multiple interconnected levels of neuronal function. Ion-channel modulation, neurotransmitter release, gene transcription, synaptic remodeling, and neurogenesis become linked within a coordinated signaling cascade.\u003c\/p\u003e\n\u003cp\u003eThis integrated mechanism makes PE-22-28 a valuable experimental tool for investigating how changes in neuronal excitability translate into durable adaptations within neural circuits.\u003c\/p\u003e\n\u003cp\u003eIts short peptide sequence further enhances research utility by allowing straightforward synthesis, purification, analytical verification, and future structural optimization. These characteristics position PE-22-28 as both a mechanistic probe and a potential lead structure for future investigations involving neuroplasticity, serotonergic signaling, and activity-dependent brain adaptation.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eSummary\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003ePE-22-28 is a synthetic seven-amino-acid research peptide developed from studies of the TREK-1 potassium channel and its role in regulating neuronal excitability.\u003c\/p\u003e\n\u003cp\u003eIts molecular mechanisms are associated with:\u003c\/p\u003e\n\u003cp\u003e• TREK-1 potassium channel inhibition\u003c\/p\u003e\n\u003cp\u003e• Increased serotonergic neuronal activity\u003c\/p\u003e\n\u003cp\u003e• BDNF and TrkB pathway activation\u003c\/p\u003e\n\u003cp\u003e• PI3K-Akt and Ras-MAPK signaling\u003c\/p\u003e\n\u003cp\u003e• Synaptic remodeling and dendritic spine maturation\u003c\/p\u003e\n\u003cp\u003e• Adult hippocampal neurogenesis\u003c\/p\u003e\n\u003cp\u003e• Activity-dependent neuroplasticity pathways\u003c\/p\u003e\n\u003cp\u003eAs a research peptide, PE-22-28 provides scientists with a unique tool for investigating the relationship between ion-channel modulation, neurotransmitter signaling, neuroplasticity, and neuronal resilience. Ongoing preclinical research continues to explore how TREK-1 regulation influences complex biological processes involved in learning, memory, stress adaptation, and brain function.\u003c\/p\u003e","brand":"PRG","offers":[{"title":"Pre-filled Pen","offer_id":53230044479754,"sku":null,"price":155.0,"currency_code":"EUR","in_stock":true},{"title":"Vial","offer_id":53230044512522,"sku":null,"price":130.0,"currency_code":"EUR","in_stock":true},{"title":"Nasal Spray (10 mg \/ 15 mL • 67 mcg\/spray)","offer_id":53230046544138,"sku":null,"price":90.0,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0908\/7113\/6522\/files\/pe22-28_4_1.png?v=1781774515","url":"https:\/\/www.peptideregenesis.com\/products\/pe-22-28","provider":"PRG","version":"1.0","type":"link"}